---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036399"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:45:20.118214+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M

## Summary
- Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.
- Adjusted EBITDA $44.5M, up ~592% YoY; gross margin improved to 53.6% from 27.8%.
- FY2024 revenue guidance raised to >$400M (from >$355M); FY2025 revenue >$445M (from >$410M).
- FY2024 GAAP net income guidance raised to >$105M; adjusted EBITDA guidance >$150M.
- Commercial-scale yield enhancement of ~20% from same starting plasma; potential benefit as early as Q4 2025.

## SEC filing metadata
- accession: 0001140361-24-036399
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124036399/0001140361-24-036399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124036399/ef20033774_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036399
- JSON: https://secwatch.observer/filing/0001140361-24-036399.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.